title: Therapies with emerging evidence of efficacy: avotermin for the improvement of scarring.
abstract: Many patients are dissatisfied with scars on both visible and non-visible body sites and would value any opportunity to improve or minimise scarring following surgery. Approximately 44 million procedures in the US and 42 million procedures in the EU per annum could benefit from scar reduction therapy. A wide range of non-invasive and invasive techniques have been used in an attempt to improve scarring although robust, prospective clinical trials to support the efficacy of these therapies are lacking. Differences in wound healing and scar outcome between early fetal and adult wounds led to interest in the role of the TGFbeta family of cytokines in scar formation and the identification of TGFbeta3 (avotermin) as a potential therapeutic agent for the improvement of scar appearance. Extensive pre-clinical and human Phase I and II clinical trial programmes have confirmed the scar improving efficacy of avotermin which produces macroscopic and histological improvements in scar architecture, with improved restitution of the epidermis and an organisation of dermal extracellular matrix that more closely resembles normal skin. Avotermin is safe and well tolerated and is currently in Phase III of clinical development, with the first study, in patients undergoing scar revision surgery, fully recruited.
authors.affiliation: Renovo, Core Technology Facility, 48 Grafton Street, Manchester M13 9XX, UK.
authors.forename: Jim
authors.initials: J
authors.lastname: Bush
authors.forename: Karen
authors.initials: K
authors.lastname: So
authors.forename: Tracey
authors.initials: T
authors.lastname: Mason
authors.forename: Nick L
authors.initials: NL
authors.lastname: Occleston
authors.forename: Sharon
authors.initials: S
authors.lastname: O'Kane
authors.forename: Mark W J
authors.initials: MW
authors.lastname: Ferguson
references.citation: Plast Reconstr Surg. 2006 Sep 15;118(4):909-918
references.pmid: 16980850
references.citation: Plast Reconstr Surg. 2002 Aug;110(2):560-71
references.pmid: 12142678
references.citation: Int J Low Extrem Wounds. 2008 Sep;7(3):160-8
references.pmid: 18757391
references.citation: J Am Coll Surg. 2008 Apr;206(4):719-30
references.pmid: 18387479
references.citation: Drug Discov Today. 2008 Nov;13(21-22):973-81
references.pmid: 18824245
references.citation: Plast Reconstr Surg. 1996 Apr;97(4):854-60
references.pmid: 8628785
references.citation: Lancet. 1992 Jan 25;339(8787):213-4
references.pmid: 1346175
references.citation: J Biol Chem. 2005 Jun 3;280(22):21329-36
references.pmid: 15799969
references.citation: Philos Trans R Soc Lond B Biol Sci. 2004 May 29;359(1445):839-50
references.pmid: 15293811
references.citation: Plast Reconstr Surg. 2009 Jul;124(1):256-265
references.pmid: 19568089
references.citation: Expert Opin Emerg Drugs. 2006 Mar;11(1):39-47
references.pmid: 16503825
references.citation: Wound Repair Regen. 2008 Jan-Feb;16(1):80-6
references.pmid: 18086295
references.citation: J Plast Reconstr Aesthet Surg. 2008;61(1):4-17
references.pmid: 17644502
references.citation: J Biomater Sci Polym Ed. 2008;19(8):1047-63
references.pmid: 18644230
references.citation: Ann Surg. 1995 Aug;222(2):146-54
references.pmid: 7639582
references.citation: Plast Reconstr Surg. 2008 May;121(5):1650-1658
references.pmid: 18453989
references.citation: Plast Reconstr Surg. 2008 Feb;121(2):487-496
references.pmid: 18300967
references.citation: Clin Plast Surg. 2009 Apr;36(2):307-13, viii
references.pmid: 19309655
references.citation: Lancet. 2009 Apr 11;373(9671):1264-74
references.pmid: 19362676
references.citation: Dermatol Surg. 2009 Aug;35(8):1172-80
references.pmid: 19250300
references.citation: Int J Biochem Cell Biol. 1997 Jan;29(1):63-78
references.pmid: 9076942
references.citation: Plast Reconstr Surg. 2008 Oct;122(4):1068-1078
references.pmid: 18827639
references.citation: J Cell Sci. 1995 Mar;108 ( Pt 3):985-1002
references.pmid: 7542672